Delving into the Latest Updates on NF-6505 with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Target

thrombin

Mechanism

thrombin inhibitors(Factor IIa inhibitors)

Therapeutic Areas

Cardiovascular Diseases

Active Indication-

Inactive Indication

Venous Thrombosis

Originator Organization

Japan Energy, Inc.

Active Organization-

Inactive Organization

Japan Energy, Inc.Daiichi Fine Chemical Co., Ltd.

Drug Highest PhaseDiscontinuedPreclinical

First Approval Date-

Regulation-

NF-6505, a bi-O-Tyr-sulfated decapeptide, which specifically interacts with the anion-binding exosite of the thrombin molecule, was chemically synthesized and assessed for its antithrombotic effects in vitro and in vivo. The IC50 value of this peptide on fibrin-clot formation in vitro was about 0.05 microgram/ml, which indicated a potency similar to that of a recombinant hirudin. NF-6505 caused a 2-fold prolongation of activated partial thromboplastin time when intravenously administered at 1 mg/kg in rats. In a rat venous thrombosis model, a bolus intravenous administration of this peptide dose-dependently inhibited the thrombus formation with an ED50 value of 0.03 mg/kg, a value smaller than that of recombinant hirudin (ED50 = 0.1 mg/kg) or of argatroban (ED50 = 0.2 mg/kg). These results suggest that NF-6505 is a highly potent and safe agent for the clinical treatment of venous thrombosis diseases.

100 Deals associated with NF-6505

Login to view more data